glp 1 drug manufacturers GLP-1 Manufacturing: Expansion & Tech Transfer GLP-1 Market Trends and Global
Description
Obesity has been demonstrated to raise the risk of high blood pressure in addition to CVD (43)
This may result from altered gut motility or changes in intestinal fluid secretion
The use of short acting GLP-1RA drugs has shown to improve glycemic control and promote insulin sectretion (53)
Oral dual GLP-1/GIP agonists and oral GLP-1/glucagon agonists are in preclinical and early clinical development at several pharmaceutical companies
doi:10.1016/j.peptides.2020.170434 122
